Rep. Gilbert Cisneros has filed a Periodic Transaction Report with the U.S. House of Representatives disclosing the sale of common stock in Crinetics Pharmaceuticals, Inc. (CRNX). The transaction, dated July 30, 2026, was made by the member of Congress personally and falls within the disclosed amount range of $15,001 to $50,000. The filing lists the holding as passing through 150 Main Street Trust before reaching Bank of America, the brokerage on record.
Under the STOCK Act, members of Congress and certain staff are required to publicly report trades in individual stocks, bonds, and other securities within a set window after execution. This filing represents a routine compliance disclosure of that kind. Our internal classification tags this event simply as a congress sale, meaning it reflects a sell-side transaction reported by a sitting House member rather than any signal about the company’s underlying business or prospects.
A Notable Timing Overlap
What makes this filing worth flagging is its proximity to another CRNX-related transaction. Company insider Struthers Richard Scott also sold shares of Crinetics Pharmaceuticals, with a disclosed value of $99,979, on August 7, 2026 — just eight days after Cisneros’s reported sale date and well within the 30-day window our tracking system uses to flag related activity in the same security.
Insider sales by corporate officers or directors are separately regulated under SEC rules and disclosed through different filings (typically Form 4), distinct from the congressional STOCK Act reporting framework. The fact that both a member of Congress and a company insider reported sales of the same stock within a short span of each other does not, on its own, indicate coordination, shared information, or any wrongdoing by either party. Lawmakers and corporate insiders operate under separate disclosure regimes for different legal reasons, and overlapping activity in a widely held or actively traded stock can occur for many unrelated reasons, including portfolio rebalancing, tax planning, or compensation-related vesting schedules.
Still, whoisbuyingnow.com tracks these clusters because they can be useful context for readers following how public officials manage disclosed assets alongside broader market activity in the same securities. Readers interested in Crinetics Pharmaceuticals may want to watch for additional Form 4 filings or subsequent STOCK Act disclosures involving CRNX in the coming weeks, as both data points here are recent and the reporting window for related transactions typically extends further.
No additional details about the rationale behind either transaction were included in the public filings reviewed for this report.